Ezetimibe tablet

Ezetimibe tablet

  • CN 106,880,598 B
  • Filed: 12/14/2015
  • Issued: 08/31/2021
  • Est. Priority Date: 12/14/2015
  • Status: Active Grant
First Claim
Patent Images

1. An ezetimibe tablet is characterized in that ezetimibe, hydroxypropyl betacyclodextrin and deoxycholic acid are dissolved in absolute ethyl alcohol, and then the solution is granulated, dried and tableted on pharmaceutically acceptable auxiliary materials;

  • wherein the weight ratio of ezetimibe to hydroxypropyl betacyclodextrin is 1;

    3-7, and the weight ratio of ezetimibe to deoxycholic acid is 1;


    the pharmaceutically acceptable auxiliary materials comprise a filling agent, a disintegrating agent and a lubricating agent, wherein the filling agent is one or more of lactose, mannitol, starch, dextrin and microcrystalline cellulose, the disintegrating agent is one or more of sodium carboxymethyl starch, crospovidone and croscarmellose sodium, and the lubricating agent is one or more of magnesium stearate, sodium fumarate stearate and talcum powder.

View all claims

    Thank you for your feedback